MAPT and Alzheimer disease: Neurodegeneration in AD can be evaluated through biomarkers such as Aβ42/Aβ40 levels in cerebrospinal fluid (CSF) and plasma, positron emission tomography (PET) imaging of Aβ plaques, and PET imaging of tau protein neurofibrillary tangles.